By stimulating immune effector cells to release IFN, trastuzumab may increase the levels of PD-L1 in cancer cells that overexpress HER2, which could result in resistance to trastuzumab in anti-HER2 therapy (Chaganty et al., 2018). This evidence concerns the gene ERBB2 and cancer.